Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Abstract: This manuscript focuses on effective modulation techniques that enable the extension of soft-switching operations for a three-phase three-level dual active bridge under light-load conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results